In accordance with article 5 of the Spanish Law RDL1/2015, the information set out in the following sections is intended for healthcare professionals.

Access to this information and all use which may be made thereof or of these contents is exclusive responsibility of those who use them. Noventure will not be held liable for any illegal or improper use or for the manipulation of the contents and information included in these pages.

New publication for Utipro® Plus / Utipro® Plus AF

Let’s celebrate 2022 with a new paper on Utipro® Plus and Utipro® Plus AF!! We are pleased to announce the publication of a meta-analysis in which the benefit of the combination of a mucoprotectant (xyloglucan or an equivalent substance), hibiscus and propolis in the management of uncomplicated urinary tract infections has been evaluated. Among different available publications, three of them were integrated into the final analysis leading the authors to interesting conclusions: “In the era of antibiotic resistance, an antibiotic-sparing approach presents an interesting alternative treatment of uncomplicated cystitis in women…“ and “A medical device containing xyloglucan, hibiscus and propolis is superior to comparator regimens in terms of clinical effectiveness in adult women with microbiologically confirmed or clinical suspicion of uncomplicated cystitis and is associated with a high patient compliance”, thus reinforcing the usefulness of Utipro® Plus/Utipro® Plus AF in acute and recurrent uncomplicated UTIs.

Read more
Do you know Noventure?

Do you know Noventure? You may know that Noventure is a Spanish company from Barcelona, part of Ferrer, specialized in medical devices & innovative food supplements.
But... who are we in the team, what do we actually do and most importantly... how do we do it❓
Follow us on LinkedIn to find out all the details of our work through short videos.
Stay tuned to our LinkedIn profile following #NoventureFaces

You can see all available videos of #NoventureFaces here: YOUTUBE channel

Read more
New publication: Omega-3 Long-Chain Polyunsaturated Fatty Acids in the Elderly: A Review Pietro Gareri. OBM Geriatrics 2022; 6(2), doi:10.21926/obm.geriatr.2202198

Available studies suggest that omega-3 PUFAs exert pleiotropic effects on cognitive decline, mood, the cardiovascular system, bone and muscle health, vascular endothelium, and immune function. 

Read more